bioRxiv · 10.1101/2020.06.01.127829
Targeted Intracellular Degradation of SARS-CoV-2 RBD via Computationally-Optimized Peptide Fusions
Abstract
The COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has elicited a global health crisis of catastrophic proportions. With no approved cure or vaccine currently available, there is a critical need for effective antiviral strategies. In this study, we report a novel antiviral platform, through computational design of ACE2-derived peptides which both target the viral spike protein receptor binding domain (RBD) and recruit E3 ubiquitin ligases for subsequent intracellular degradation of SARS-CoV-2 in the proteasome. Our engineered peptide fusions demonstrate robust RBD degradation capabilities in human cells, thus prompting their further experimental characterization and therapeutic development.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Chatterjee, P., Ponnapati, M., Jacobson, J. M.. 2020-06-01. Targeted Intracellular Degradation of SARS-CoV-2 RBD via Computationally-Optimized Peptide Fusions. https://doi.org/10.1101/2020.06.01.127829
Cite the original work for its findings. Save a collection to share your selection of sources.